
New research from the American Cancer Society comparing pre-pandemic cancer screening prevalence to the second year of the COVID-19 pandemic in the United States showed a 1.1 million decrease in breast cancer screenings, a 4.4 million decrease in cervical cancer screening and a 600,000 decrease in prostate cancer screenings.











































